期刊
DRUGS OF THE FUTURE
卷 32, 期 11, 页码 973-984出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2007.032.11.1140690
关键词
-
The alarming worldwide increase in multicirug-resistant and extensively drug-resistant tuberculosis (TB) calls for new anti mycobacterial drugs against new types of targets which are less likely to undergo mutations that lead to drug resistance. The discovery that three genes of Mycobacterium tuberculosis, recA, dnaB and sufB, are interrupted by inteins, which must be excised from inactive precursor proteins by the process of protein splicing to yield functional proteins, suggests protein splicing as a novel target for anti-TB drugs. Since two of these genes are essential for growth and the third predisposes to drug resistance mutations, protein splicing inhibitors, which disable two separate vital functions and at the same time suppress mutation rates, would be unlikely to elicit drug resistance. A robust, protein-based high-throughput screening system for protein splicing inhibitors has been developed and used for screening small-molecule compound libraries, leading to more than 50 confirmed positives with IC50 values in the low micromolar range. Most of the confirmed protein splicing inhibitors are electrophiles that inhibit protein splicing irreversibly by binding to the catalytic cysteine residue. Lead optimization, aided by docking to the known crystal structure of the RecA intein, should yield a valuable new class of antimycobacterial drugs for the treatment of drug-resistant TB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据